Advancing Pharmacogenomics in the UK
More than 20 years ago, the Human Genome Project mapped the genes that make us who we are, paving the way for using information about an individual’s genes in healthcare. ‘Pharmacogenomics’ studies how our genes influence our response to medicines. We know that differences in our genes can determine whether a medicine works well, fails to work, or causes series side effects. Pharmacogenomic knowledge is now at a stage where it can benefit people receiving medical treatment.
The Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) is dedicated to accelerating the safe and effective use of pharmacogenomics in healthcare. We develop guidelines, industry pathways, and educational platforms to support regulators, healthcare professionals, and researchers, while ensuring patient and public input shapes the future of genomic medicine.
Through collaboration across academia, industry, and the NHS, our goal is to make precision medicine a reality, improving patient outcomes and fostering innovation across the UK.
Contact:
Angela Cucchi, Project Co-Ordinator, angela.cucchi@liverpool.ac.uk
Our supporting partners:
What is CERSI-PGx?
-
New Module Launched on CERSI-PGx Training and Education Platform
Responsive Regulatory Action from Signals in Post-Marketing Surveillance — Toxicity Case Studies This module addresses the significance of post-marketing pharmacogenomic (PGx) surveillance and its role…
-
CERSI-PGx Workshop – 10 September 2026
We would like to extend an invitation to all our CERSI-PGx friends and colleagues to join us at the next CERSI-PGx on-line workshop to be…
-
New CERSI-PGx Guideline published!
We are delighted to announce that the CERSI-PGx has published its latest PGx prescribing guideline. We have made recommendations for the optimisation of clozapine prescribing…
Read more News & Events articles →